You are in: eMedicine Specialties > Dermatology > INTERNAL MEDICINE Acrokeratosis NeoplasticaArticle Last Updated: Aug 17, 2005AUTHOR AND EDITOR INFORMATIONAuthor: Karen Allen, MD, Consulting Dermatologist Karen Allen is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology Editors: Jean-Hilaire Saurat, MD, Chair, Professor, Department of Dermatology, University of Geneva, Switzerland; David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic; Jeffrey Meffert, MD, Assistant Clinical Professor of Dermatology, University of Texas Health Science Center-San Antonio; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System Author and Editor Disclosure Synonyms and related keywords: Bazex syndrome, paraneoplastic acrokeratosis INTRODUCTIONBackgroundAcrokeratosis neoplastica (AN) is a rare psoriasiform dermatosis that is associated consistently with internal malignancy, usually squamous cell carcinoma (SCC) of the upper aerodigestive tract. Skin manifestations include acute onset of onychodystrophy and violaceous scaly patches on the helices, nose, and malar and acral surfaces. Usually, skin manifestations precede diagnosis of the malignancy. The term Bazex syndrome describes 2 different entities: AN and the genetic syndrome of basal cell carcinomas, follicular atrophoderma, hypotrichosis, and hypohidrosis or hyperhidrosis. PathophysiologyThe skin manifestations of AN parallel the disease course, suggesting the presence of circulating antibodies to tumor antigens. Cytokines may play a role. FrequencyUnited StatesApproximately 125 cases have been reported in the literature. Mortality/Morbidity
SexIn one review, 105 of 113 cases were in males. AgeMean age of onset is 61 years. CLINICALHistory
Causes
DIFFERENTIALSContact Dermatitis, Allergic Lupus Erythematosus, Acute Lupus Erythematosus, Subacute Cutaneous Onycholysis Onychomycosis
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Betamethasone (Diprolene, Betatrex) |
|---|---|
| Description | For inflammatory dermatosis responsive to steroids. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability. |
| Adult Dose | Apply thin film bid/qid until response |
| Pediatric Dose | Administer as in adults with caution |
| Contraindications | Documented hypersensitivity; paronychia; cellulitis; impetigo; angular cheilitis; erythrasma; erysipelas; rosacea; perioral dermatitis; and acne |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use in skin with decreased circulation; can cause atrophy of groin, face, and axillae; if infection develops and is not responsive to antibiotic treatment, discontinue until infection is under control; do not use monotherapy to treat widespread plaque psoriasis |
For treatment of vitamin D deficiency or prophylaxis of vitamin D deficiency. Vitamin D and its analogs have profound effects on cellular proliferation and differentiation in addition to immunomodulatory effects. Calcipotriene, a vitamin D analog, is a well-accepted treatment for psoriasis, which is a condition that shares some similarities with AN. However, the reports of efficacy in the treatment of AN with vitamin D are anecdotal.
| Drug Name | Cholecalciferol (Delta-D, Vitamin D-3) |
|---|---|
| Description | Stimulates absorption of calcium and phosphate from small intestine and promotes release of calcium from bone into blood. Antiproliferative and anti-inflammatory effects on skin. |
| Adult Dose | Delta-D: 400 IU PO qd Vitamin D-3: 1000 IU PO qd Calcitriol: 0.25-1 mcg PO qd |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; hypercalcemia; malabsorption syndrome |
| Interactions | Colestipol, mineral oil, and cholestyramine may decrease absorption of ergocalciferol from small intestine; thiazide diuretics may increase effects of vitamin D; may interfere with calcium channel blockers |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in impaired renal function, renal stones, heart disease, or arteriosclerosis |
| Media file 1: Bazex syndrome. Acquired palmar keratoderma in a woman with a history of breast cancer and recent primary lung cancer. Courtesy of Jeffrey J Meffert, MD. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Bazex syndrome. Violaceous psoriasiform dermatitis on the ankles (same patient as in Image 1). Lung cancer appeared to be in remission; both keratoderma and psoriasiform plaques resolved quickly with clobetasol ointment. Courtesy of Jeffrey J Meffert, MD. | |
![]() | View Full Size Image | Media type: Photo |
Acrokeratosis Neoplastica excerpt
Article Last Updated: Aug 17, 2005